News Article

Baird Capital, global private equity group, is investing in Newmarket Strategy, a fast-growing specialist healthcare, medtech and life sciences consultancy specialising in market access.

Candesic is pleased to have provided commercial due diligence to Baird Capital. The Candesic team, was led by Managing Partner Dr. Leonid Shapiro, Engagement Manager Fabio Ruffinoni and Associate Teresa Pla Prats. The project team delivered valuable insights focusing on validating market size, analysing company performance, prioritising strategic opportunities, and quantifying growth prospects.

Newmarket Strategy is recognised for its expertise across the bench-to-bedside value chain. It is able to provide comprehensive market access and go-to-market support (and related services) to pharmaceutical and healthcare companies. Newmarket’s services are considered mission-critical for companies seeking reimbursement and value in the UK and other international markets; particularly given the complexity of the systems and processes for pricing and reimbursement. It also has key strengths in policy and government affairs. 

With this strong positioning and significant growth potential, Newmarket Strategy is well-placed to capitalise on opportunities in the dynamic healthcare and life sciences sectors. We wish Baird Capital and the Newmarket team every success in their future business together.